Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
L. crispatus CTV-05 vs Semaglutide: Semaglutide has the stronger overall evidence (8.5 vs 6/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
VAGINAL USE ONLY, by applicator: 2 x 10^9 CFU per dose. The phase 2b regimen was one dose daily for 5 days in week 1, then twice weekly for a further 10 weeks — always started after a completed course of vaginal metronidazole gel.
any
Vaginal applicator delivering L. crispatus CTV-05
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
11-week dosing course, measured at 12 weeks
n/a
Days 10-28
Persisting to 24 weeks
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.
N Engl J Med (2020) · Rct · n=228
Recurrence of bacterial vaginosis by week 12: 30% (46/152) with Lactin-V vs 45% (34/76) with placebo; risk ratio 0.66 (95% CI 0.44-0.87), P=0.01
Response to Antibiotic Treatment of Bacterial Vaginosis Predicts the Effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the Prevention of Recurrent Disease.
Sex Transm Dis (2024) · Observational
This is a POST HOC analysis of the already-completed phase 2b LACTIN-V trial, not a new trial
Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial.
Lancet Microbe (2022) · Rct · n=66
Vaginal IL-1α was significantly lower with LACTIN-V (β 0.310, SE 0.149; p=0.042)
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Semaglutide has a higher evidence score (8.5/10 vs 6/10) and wins in 2 of 3 categories.
No known interactions between L. crispatus CTV-05 and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.